25
Participants
Start Date
April 15, 2022
Primary Completion Date
February 22, 2025
Study Completion Date
November 5, 2025
Orelabrutinib
150 mg capsules administered orally once daily (28-day cycles). Until 12 or 24 cycles and following BM undetectable MRD, or disease progression, or intolerant toxicity.
Obinutuzumab
1000 mg administered intravenously once on Day 1, 8, 15 of first cycle and on Day 1 of following cycles for maximal 12 cycles (28-day cycles).
Fludarabine
25mg/m2/day administered intravenously on Day 1-3 for every cycle (at most 6 cycles, 28-day cycles).
Cyclophosphamide
250mg/m2/day administered intravenously on Day 1-3 for every cycle (at most 6 cycles, 28-day cycles).
RECRUITING
Department of Haematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjin
The First Affiliated Hospital with Nanjing Medical University
OTHER